Zenas BioPharma

Update in progress

ZBIO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Zenas BioPharma, Inc. is a clinical-stage biopharma company focused on immunology-based therapies. Its lead candidate, obexelimab, is a bifunctional antibody targeting CD19 and FcγRIIb for various inflammatory and immunology indications, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. Other programs include ZB002 (anti-TNFα), ZB004 (extended-half-life CTLA-4-Ig), and ZB001 (anti-IGF-1R). Founded 2019, headquartered in Waltham, MA; renamed in 2023 from Zenas BioPharma (Cayman) Limited.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive